Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study Testing the Safety and Effects of FB102 in Healthy Volunteers

The purpose of this Phase 1 trial is to evaluate the safety and effects of FB-102 in healthy volunteers following single and multiple doses.

Participants needed: 56
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Forte Biosciences, Inc.Updated: Jun 3, 2026Locations: 1
Eligibility criteria

Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive, at Screening. [+5]

Any clinically significant medical condition malignancy allergy infection or imm... [+3]

Read more
Status: Recruiting

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).

Participants needed: 32
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Forte Biosciences, Inc.Updated: Nov 20, 2025Locations: 6
Eligibility criteria

Males aged 18-60 years and females aged 18-75 years at Screening. [+2]

Other types of alopecia (e.g., diffuse AA, traction, scarring alopecia, telogen... [+2]

Read more
Status: Recruiting

Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease

This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.

Participants needed: 100
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Forte Biosciences, Inc.Updated: Nov 18, 2025Locations: 1
Eligibility criteria

Men and women aged 18 to 70 years at Screening. [+3]

Uncontrolled CeD and/or active signs/symptoms of CeD, in the opinion of the Inve... [+1]

Read more
Status: Recruiting

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo

A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.

Participants needed: 64
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Forte Biosciences, Inc.Updated: Nov 20, 2025Locations: 6
Eligibility criteria

Males and females aged ≥ 18 to 75 years at time of Screening. [+2]

Currently have active forms of other hypopigmentation (including but not limited... [+2]

Read more